Canada - English - Health Canada

novopharm limited - erythromycin (erythromycin ethylsuccinate) - powder - 400mg - erythromycin (erythromycin ethylsuccinate) 400mg - erythromycins

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - erythromycin 30 mg in 1 g - erythromycin and benzoyl peroxide topical gel usp is indicated for the topical treatment of acne vulgaris. erythromycin and benzoyl peroxide topical gel usp is contraindicated in those individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 20 mg in 1 ml - erythromycin topical solution usp, 2% is indicated for the topical treatment of acne vulgaris. erythromycin topical solution usp, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - erythromycin ethyl succinate, quantity: 468 mg (equivalent: erythromycin, qty 400 mg) - oral liquid, powder for - excipient ingredients: sorbitol; propylene glycol alginate; sodium citrate dihydrate; erythrosine; aspartame; sodium benzoate; colloidal anhydrous silica; flavour - streptococcus pyogenes (group a beta-haemolytic streptococcus). upper and lower respiratory tract, skin and skin structure infections of mild to moderate severity. when oral medication is given, patient must comply with the prescribed regimen. therapeutic dose should be administered for at least 10 days. alpha haemolytic streptococci (viridans group). no controlled clinical efficacy trials have been conducted, however oral erythromycin has been suggested by the american heart association and the american dental association for use in bacterial endocarditis prophylaxis prior to dental/surgical procedures of the upper respiratory tract in penicillin-hypersensitive patients with a history of rheumatic, congenital or other acquired valvular heart disease. erythromycin is unsuitable prior to genitourinary or gastrointestinal tract surgery. staphylococcus aureus. acute infections of skin and skin structure of mild to moderate severity. bacterial resistance may emerge during treatment, hence cultures and sensitivity

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - erythromycin ethyl succinate, quantity: 234 mg (equivalent: erythromycin, qty 200 mg) - oral liquid, powder for - excipient ingredients: sorbitol; propylene glycol alginate; sodium citrate dihydrate; erythrosine; aspartame; sodium benzoate; colloidal anhydrous silica; flavour - streptococcus pyogenes (group a beta-haemolytic streptococcus). upper and lower respiratory tract, skin and skin structure infections of mild to moderate severity. when oral medication is given, patient must comply with the prescribed regimen. therapeutic dose should be administered for at least 10 days. alpha haemolytic streptococci (viridans group). no controlled clinical efficacy trials have been conducted, however oral erythromycin has been suggested by the american heart association and the american dental association for use in bacterial endocarditis prophylaxis prior to dental/surgical procedures of the upper respiratory tract in penicillin-hypersensitive patients with a history of rheumatic, congenital or other acquired valvular heart disease. erythromycin is unsuitable prior to genitourinary or gastrointestinal tract surgery. staphylococcus aureus. acute infections of skin and skin structure of mild to moderate severity. bacterial resistance may emerge during treatment, hence cultures and sensitivity

United States - English - NLM (National Library of Medicine)

perrigo new york inc - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin-benzoyl peroxide topical gel is indicated for the topical treatment of acne vulgaris. erythromycin-benzoyl peroxide topical gel is contraindicated in those individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

perrigo new york inc - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin-benzoyl peroxide topical gel is indicated for the topical treatment of acne vulgaris. erythromycin-benzoyl peroxide topical gel is contraindicated in those individuals who have shown hypersensitivity to any of its components.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - erythromycin - gastro-resistant tablet - 250mg

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) -

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) -